These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 16715360)

  • 1. Nontoxic suramin as a chemosensitizer in patients: dosing nomogram development.
    Chen D; Song SH; Wientjes MG; Yeh TK; Zhao L; Villalona-Calero M; Otterson GA; Jensen R; Grever M; Murgo AJ; Au JL
    Pharm Res; 2006 Jun; 23(6):1265-74. PubMed ID: 16715360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study of low-dose suramin as a chemosensitizer in patients with advanced non-small cell lung cancer.
    Villalona-Calero MA; Wientjes MG; Otterson GA; Kanter S; Young D; Murgo AJ; Fischer B; DeHoff C; Chen D; Yeh TK; Song S; Grever M; Au JL
    Clin Cancer Res; 2003 Aug; 9(9):3303-11. PubMed ID: 12960116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Noncytotoxic suramin as a chemosensitizer in patients with advanced non-small-cell lung cancer: a phase II study.
    Villalona-Calero MA; Otterson GA; Wientjes MG; Weber F; Bekaii-Saab T; Young D; Murgo AJ; Jensen R; Yeh TK; Wei Y; Zhang Y; Eng C; Grever M; Au JL
    Ann Oncol; 2008 Nov; 19(11):1903-9. PubMed ID: 18632723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nontoxic suramin treatments enhance docetaxel activity in chemotherapy-pretreated non-small cell lung xenograft tumors.
    Lu Z; Wientjes TS; Au JL
    Pharm Res; 2005 Jul; 22(7):1069-78. PubMed ID: 16028007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I clinical trial of the novel platin complex dicycloplatin: clinical and pharmacokinetic results.
    Li S; Huang H; Liao H; Zhan J; Guo Y; Zou BY; Jiang WQ; Guan ZZ; Yang XQ
    Int J Clin Pharmacol Ther; 2013 Feb; 51(2):96-105. PubMed ID: 23127487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I pharmacokinetic study of bexarotene with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer (NSCLC).
    Rodon J; Jacobs CD; Chu Q; Rowinsky EK; Lopez-Anaya A; Takimoto CH; Wakelee HA
    Cancer Chemother Pharmacol; 2012 Mar; 69(3):825-34. PubMed ID: 22057853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suramin: development of a population pharmacokinetic model and its use with intermittent short infusions to control plasma drug concentration in patients with prostate cancer.
    Jodrell DI; Reyno LM; Sridhara R; Eisenberger MA; Tkaczuk KH; Zuhowski EG; Sinibaldi VJ; Novak MJ; Egorin MJ
    J Clin Oncol; 1994 Jan; 12(1):166-75. PubMed ID: 8270974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suramin as a chemosensitizer: oral pharmacokinetics in rats.
    Ogden A; Wientjes MG; Au JL
    Pharm Res; 2004 Nov; 21(11):2058-63. PubMed ID: 15587928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I study of biweekly paclitaxel and carboplatin for frail patients with advanced non-small cell lung cancer.
    Yanagitani N; Tsuchiya S; Kaira K; Sunaga N; Tsuchiya Y; Sato K; Watanabe S; Nomura S; Sakai S; Saito R; Mori M
    Am J Clin Oncol; 2007 Oct; 30(5):487-91. PubMed ID: 17921708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetic analysis of patritumab, a HER3 inhibitor, in subjects with advanced non-small cell lung cancer (NSCLC) or solid tumors.
    Yoshiba S; Jansen M; Matsushima N; Chen S; Mendell J
    Cancer Chemother Pharmacol; 2016 May; 77(5):987-96. PubMed ID: 27017616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paclitaxel (1-hour) and carboplatin (area under the concentration-time curve 7.5) in advanced non-small cell lung cancer: a phase II study of the Fox Chase Cancer Center and its network.
    Langer CJ; Millenson M; Rosvold E; Litwin S; McAleer CA; Bonjo CA; Ozols R
    Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-81-S12-88. PubMed ID: 9331128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I evaluation of low-dose suramin as chemosensitizer of doxorubicin in dogs with naturally occurring cancers.
    Kosarek CE; Hu X; Couto CG; Kisseberth WC; Green EM; Au JL; Wientjes MG
    J Vet Intern Med; 2006; 20(5):1172-7. PubMed ID: 17063712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I study of suramin with once- or twice-monthly dosing in patients with advanced cancer.
    Ryan CW; Vokes EE; Vogelzang NJ; Janisch L; Kobayashi K; Ratain MJ
    Cancer Chemother Pharmacol; 2002 Jul; 50(1):1-5. PubMed ID: 12111104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequence effect of docetaxel and carboplatin on toxicity, tumor response and pharmacokinetics in non-small-cell lung cancer patients: a phase I study of two sequences.
    Ando M; Saka H; Ando Y; Minami H; Kuzuya T; Yamamoto M; Watanabe A; Sakai S; Shimokata K; Hasegawa Y
    Cancer Chemother Pharmacol; 2005 Jun; 55(6):552-8. PubMed ID: 15856233
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A feasibility study of postoperative adjuvant therapy of carboplatin and weekly paclitaxel for completely resected non-small cell lung cancer.
    Yamashita Y; Kataoka K; Ishida T; Matsuura M; Seno N; Mukaida H; Miyahara E; Miyata Y; Okita R; Shimizu K; Watari M; Okumichi T; Okada M
    J Thorac Oncol; 2008 Jun; 3(6):612-6. PubMed ID: 18520800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I and pharmacokinetic study of carboplatin and paclitaxel with a biweekly schedule in patients with advanced non-small-cell lung cancer.
    Ichiki M; Gohara R; Fujiki R; Hoashi S; Rikimaru T; Aizawa H
    Cancer Chemother Pharmacol; 2003 Jul; 52(1):67-72. PubMed ID: 12743738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose therapy with carboplatin and paclitaxel in non-small cell lung cancer.
    Socinski MA; Shea TC
    Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-45-S12-51. PubMed ID: 9331121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I trial of paclitaxel plus carboplatin in untreated patients with advanced non-small cell lung cancer.
    Kelly K; Pan Z; Murphy J; Huffman DH; Bunn PA
    Clin Cancer Res; 1997 Jul; 3(7):1117-23. PubMed ID: 9815791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC).
    Cohen RB; Langer CJ; Simon GR; Eisenberg PD; Hainsworth JD; Madajewicz S; Cosgriff TM; Pierce K; Xu H; Liau K; Healey D
    Cancer Chemother Pharmacol; 2007 Jun; 60(1):81-9. PubMed ID: 17031646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequential versus concurrent paclitaxel and carboplatin for the treatment of advanced non-small cell lung cancer in elderly patients and patients with poor performance status: results of two Phase II, multicenter trials.
    Marsland TA; Garfield DH; Khan MM; Look RM; Boehm KA; Asmar L
    Lung Cancer; 2005 Jan; 47(1):111-20. PubMed ID: 15603861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.